And a bit of an update on Replimune's OV. I don't recall seeing this posted, so apologies if it has been already. Makes the Vaxinia results look a lot better....
After Data Miss in Lead Cancer Indication, Replimune Maps Path for Oncolytic Virus - MedCity News.
Replimune’s lead therapeutic candidate did not meet the two main goals of a study intended to support an FDA submission in cutaneous squamous cell carcinoma. But Replimune’s therapy, an oncolytic virus, has better data in melanoma, and the company plans a 2024 FDA submission in this skin cancer.
Link for article: After Data Miss in Lead Cancer Indication, Replimune Maps Path for Oncolytic Virus - MedCity News
Why IMU is a multi multi bagger, page-20502
Add IMU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
5.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $371.8M | |||
| Open | High | Low | Value | Volume |
| 5.0¢ | 5.0¢ | 4.8¢ | $521.9K | 10.58M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 17 | 1612511 | 4.9¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 5.0¢ | 3882781 | 14 |
View Market Depth
| Last trade - 16.10pm 02/10/2024 (20 minute delay) ? |
| IMU (ASX) Chart |